SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced its financial results for the first quarter ended March 31, 2007.
Optimer reported a net loss applicable to common stockholders for the first quarter of 2007 of $24.5 million or, $1.75 per common share. This compares to a net loss applicable to common stockholders in the first quarter of 2006 of $2.1 million, or $0.85 per common share. Results of operations for the first quarter of 2007 had an increase in research and development expenses of $21.3 million primarily due to a $20 million payment to Par Pharmaceutical Companies, Inc. to reacquire the North American rights to OPT-80, formerly known as PAR-101 or Difimicin.
